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PROMISE UTILITY DOCTRINE AND 
COMPATIBILITY UNDER NAFTA: 
EXPROPRIATION AND CHAPTER 11 
CONSIDERATIONS 
Freedom-Kai Phillips* 
ABSTRACT: The 2013 filing by Eli Lilly of a notice of arbitration under Chapter 11 of 
NAFTA relating to the application of the promise utility doctrine in Canadian 
jurisprudence brought to light latent tensions relating to domestic patent standards, 
perceived barriers to innovation, and international investment standards. This paper 
explores applicable NAFTA obligations and patent regimes in an effort to identify points 
of convergence and divergence, and argues that the promise utility doctrine while 
differentiated on procedural grounds domestically has significant substantive alignment 
across jurisdictions, and is overall consistent with the standard of treatment established 
under NAFTA. The promise utility doctrine, which is grounded in a harmonized view of 
the theoretical underpinnings of the patent bargain, progressively articulates the enduring 
need to maintain highly-specific disclosure standards to support sound patent practices, 
maintain ongoing innovation, and dissuade otherwise speculative or suppressive 
practices. 
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I. INTRODUCTION 
Invalidation of a patent for lack of utility based on the promise utility 
doctrine identifies important questions pertaining to the compatibility of such an 
approach with pre-existing trade obligations, particularly those established under 
the North American Free Trade Agreement (“NAFTA”).1 In 2013, Eli Lilly & 
Company (“Eli Lilly”) filed a notice of arbitration under NAFTA claiming that 
the recent invalidation of two patents based on the application of the promise 
doctrine was tantamount to direct or indirect expropriation.2 This paper will 
explore the validity and compatibility of the promise utility doctrine as 
articulated in Canadian jurisprudence with investor-state protections as 
established under NAFTA through a review of the current Chapter 11 dispute 
initiated by Eli Lilly over the invalidation of patents for Zyprexa and Strattera. 
First, a brief outline of the Chapter 11 dispute will be offered as background, 
including both patent and procedural historical summaries. Second, applicable 
investor-state protections as established under NAFTA are summarized. Third, 
patent standards across NAFTA jurisdictions are discussed with particular 
emphasis on highlighting the evolution and alignment of the promise utility 
doctrine. Fourth, the promise utility doctrine is critically appraised to assess 
consistency with established NAFTA obligations, with specific emphasis on 
direct and in-direct expropriation. Finally, concluding thoughts are offered, 
highlighting points of convergence and divergence. The promise utility doctrine 
marks a progressive evolution in the assessment of a patent’s utility which, while 
initially raising prima facie concerns over incompatibility, remains consistent 
with NAFTA obligations. 
While consistent with the position of the Government of Canada in the 
dispute overall, it is on the scope of Intellectual Property (“IP”) system alignment 
and the applicability of the police powers exception to expropriation where our 
positions slightly diverge. I assert that IP regimes under NAFTA jurisdictions are 
far more harmonized theoretically and substantively than previously recognized, 
with mechanical deviation relating to the operative components of the regime to 
address a utility inquiry acknowledged. I also note the unique market 
circumstances which have fostered the promise utility doctrine. Furthermore, the 
fair, non-arbitrary and transparent judicial application of the patent bargain 
through the promise utility doctrine fits within the police powers exception to 
expropriation. International law cannot be utilized to justify dilution of the patent 
system to the point where speculative patent practices are encouraged or 
accepted. The promise utility doctrine marks an inflection point for patent 
interpretation in an age of unbounded innovation, an evolutionary step rightly 
grounded in a harmonized view of the theoretical underpinnings of the patent 
bargain, and a progressive approach to patent interpretation which benefits the 
global patent community. 
 
 1 North American Free Trade Agreement, U.S.-Can.-Mex., Dec. 17, 1992, 32 I.L.M. 639. 
 2 Eli Lilly & Co. v. Canada, Notice of Arbitration, UNCT/14/12, (Sept. 12, 2013). 
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II. BACKGROUND 
This section aims to briefly outline the factual elements which underlay the 
dispute as background. First, the historical backdrop underlying the successful 
granting of Canadian Patent No. 2,041,113 for “Zyprexa,” and Canadian Patent 
No. 2,209,735 for “Strattera” is summarized. Second, the procedural history 
relating to challenges to the aforementioned patents is discussed. The evidentiary 
basis supporting and the procedural steps which led to the invalidation of the 
Zyprexa and Strattera patents provides valuable context and insight to consider in 
light of the Investor-State expectation of fair and equitable treatment (“FET”). 
A. Patent History: Zyprexa and Strattera 
Founded in 1876, Eli Lilly has progressively established a long history of 
conducting innovative research and development in the pharmaceutical sector,3 
and like other cost-intensive sectors, is highly dependent upon the use of IP 
rights system, particularly patents, to recuperate the significant investment 
associated with drug development.4 Zyprexa (olanzapine), a 
thienobenzodiazepine derivative commercially used in the treatment of 
schizophrenia, was first developed, clinically tested, and patented in the United 
Kingdom,5 leading to patent applications in a total of eighty-one jurisdictions 
including Canada and the United States.6 Canadian Patent No. 2,041,113 (the 
“113 patent”) for Zyprexa was filed April 24, 1991 and issued July 14, 1998, and 
covers the pharmaceutical application of 2-methyl-thieno-benzodiazepine to treat 
disorders to the central nervous system, schizophrenia, schizophreniform disease, 
acute mania, and mild anxiety states.7 The 113 patent was a “selection patent,” 
insomuch as it selected specific compounds based on a previous originating 
(“genus”) patent, Canadian Patent No. 1,075,687 (the “687 patent”), which 
covered a widespread set of compounds based on the common three-ring 
molecular structure “thienobenzodiazepine.”8 United States Patent No. 5,229,382 
was filed May 22, 1992,9 and issued July 20, 1993, and carries with it an 
equivalent scope.10 Following regulatory approval, Zyprexa entered the market in 
1996 and gained widespread application for treatment of schizophrenia.11 
Strattera (atomoxetine), an early non-stimulant based treatment for attention-
deficit hyperactivity disorder (“ADHD”), grew out of early research on the use of 
atomoxetine for treatment of depression.12 United States Patent No. 5,658,590 
 
 3 James H. Madison, Manufacturing Pharmaceuticals: Eli Lilly and Company, 1876-
1948, 18 BUSINESS AND ECONOMIC HISTORY 72, 72-78 (1989). 
 4 Paul Grootendorst, Patents and Other Incentives for Pharmaceutical Innovation, in 
Elsevier Encyclopedia of Health Economics (2014). 
 5 U.K., Patent No. 9009229.7 (issued April 25, 1990). 
 6 Eli Lilly & Co. v. Canada, Claimant’s Memorial UNCT/14/2, Lilly Obtaining Patent, ¶ 
84-85 (Sept. 29, 2014). 
 7 Canada, Patent No. 02,041,113 (issued April 24, 1991). 
 8 Eli Lilly Canada Inc. v. Novopharm Ltd., [2011] F.C. 1288, ¶ 1-2. 
 9 U.S., Patent No. 07/690,143 (issued April 23, 1991). 
 10 U.S., Patent No. 5,229,382, (issued July 20, 1993). 
 11 Canada, Claimant’s Memorial, supra note 6, ¶ 92. 
 12 Id. ¶ 118. 
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was filed on January 11, 1995,13 and issued August 19, 1997, and covers the 
“method of use” of tomoxetine for treatment of ADHD and impulse-type 
disorders.14 Filed under the Patent Cooperation Treaty on January 4, 1996 and 
published July 18, 1996, Canadian Patent No. 2,209,735 (the “735 patent”) was 
issued October 1, 2002.15 Principal evidence for the filing was a supportive 
seven-week study conducted by Massachusetts General Hospital (“MGH”), 
which was provided to Health Canada to support approval but was not disclosed 
as a component of the patent application.16 
B. Procedural History: Zyprexa and Strattera 
Both Zyprexa and Strattera follow a common procedural path resulting from 
a challenge filed by a generic drug manufacturer, with the former being in retort 
to claims of infringement and the latter being pre-emptive in nature. In the case 
of the 113 patent for Zyprexa (olanzapine), Eli Lilly claimed Novopharm, a 
Canadian generic drug manufacturer, was infringing the aforementioned patent 
in the production of “novo-olanzapine.” This question was first addressed by 
Justice O’Reilly at the Federal Court [trial judgment], with his judgment of 
October 5, 2009. Justice O’Reilly dismissed the claim of infringement on the 
basis that the 113 patent was not a valid selection patent, as at the time of patent, 
Eli Lilly had not included sufficient information to demonstrate or soundly 
predict the utility described in the patent application, and that olanzapine was 
encompassed in the previous 687 patent which lasted between 1980 to 1997.17 
The trial judgment was overturned by the Federal Court of Appeal (“FCA”) in 
the decision delivered by Justice Layden-Stevenson on July 21, 2010 [FCA 
Judgment], which held that Justice O’Reilly erred in his interpretive approach 
towards selection patents, and therefore, had fatally undermined the analysis of 
utility.18 As such, the questions of utility and the sufficiency of disclosure in the 
patent were remitted back to the Federal Court for proper consideration.19 
In the follow-up decision by the Federal Court [second trial judgment],20 
Justice O’Reilly applied the guidance provided by the FCA in considering utility 
which included: (i) affirmation that a selection patent must provide a “substantial 
advantage,” have all selected members exhibit the advantageous qualities, and 
have the selection be made on the basis of this “quality of a special character,”21 
and (ii) that while a mere scintilla of utility is generally sufficient, where a patent 
makes an explicit promise, the principle consideration must shift to “whether the 
 
 13 U.S., Patent No. 08/371,341 (issued Jan. 11, 1995). 
 14 U.S., Patent No. 5,658,590 (issued Aug. 19, 1997). 
 15 Canada, Patent No. 2,209,735 (issued July 18, 1996). 
 16 Canada, Notice of Arbitration, supra note 2, ¶ 50; Canada, Claimant’s Memorial, supra 
note 6, ¶ 119. 
 17 Eli Lilly Canada Inc. v. Novopharm Ltd., [2009] FC 1018, ¶ 154. 
 18 Eli Lilly Canada Inc v Novopharm Ltd, [2010] FCA 197, ¶ 108-109. 
 19 Id. ¶ 124. 
 20 Eli Lilly Canada Inc v Novopharm Ltd., [2011] FC 1288. 
 21 Id. ¶ 81-82; Novopharm, supra note 18, ¶ 19-22; Sanofi-Synthelabo Canada Inc v 
Apotex Inc, [2008] SCC 61, [2008] 3 SCR 265 [Sanofi-Synthelabo], relying on Re I.G. 
Farbenindustrie AG’s Patents (1930), 47 RPC 289 (Ch D). 
4
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invention does what the patent promises it will do.”22 As a selection patent, the 
113 patent was required to demonstrate utility in terms of fulfillment of a specific 
promise of a substantial advantage based on a sound prediction of that promise at 
the time the patent was filed.23 Justice O’Reilly constituted the promise of the 
113 patent to be that “olanzapine treats schizophrenia patients. . . in a markedly 
superior fashion with a better side-effects profile than other known 
antipsychotics.” Citing insufficient clinical studies and lack of a sound line of 
reasoning, Justice O’Reilly concluded that indeed, the 113 patent did not meet 
this promise at the time of patent.24 Leave was denied to both the FCA, and the 
Supreme Court of Canada (“SCC”).25 
Regarding the 735 patent for Strattera (atomoxetine), Teva Canada Limited 
(formerly Novopharm) initiated an action in Federal Court seeking a finding of 
invalidity for the aforementioned patent,26 opening the door for commercial sales 
of the generic equivalent. On September 14, 2010, Justice Barnes first 
recognized the 735 patent to be indicating an “inventive new use” of a known 
compound.27 Second, in considering utility, he cited Consolboard, AZT and the 
reasoning articulated in the consideration of the 113 patent for Zypreza; he 
reiterated that utility is a product of the invention doing what is claimed for a 
person skilled in the art, based on sufficient evidence or sound prediction at the 
time of patent.28 Utility is identified as not equitable with the treatment working 
for all patients, nor working for only a single patient. As noted by Justice Barnes, 
disclosure must sufficiently demonstrate effectiveness or support a sound 
prediction.29 Where a sound prediction is made, he cited AZT, indicating that 
disclosure in the patent must include both “factual data” and the articulated “line 
of reasoning” underlying the sound prediction to satisfy the quid pro quo of the 
patent.30 As the 735 patent was based on a sound prediction and as the MGH 
study had significant limitations,31 and was neither disclosed nor referenced in 
the patent application, the patent was found to fail for “want of disclosure.”32 The 
trial findings were affirmed upon appeal, with the July 5, 2011 decision of the 
FCA reiterating that where the factual basis supporting the predicted utility is not 
 
 22 Novopharm, [2011] FC 1288, ¶ 84; Novopharm, supra note 18, ¶ 74-77; Consolboard 
Inc v MacMillan Bloedel (Saskatchewan) Ltd, [1981] 1 S.C.R. 504, 56 C.P.R. (2d) 145; Pfizer 
Canada Inc v Canada (Minister of Health), [2008] FCA 108. 
 23 Novopharm, [2011] FC 1288, ¶ 85-88; Novopharm, supra note 18, ¶ 78. 
 24 Novopharm, [2011] FC 1288, ¶ 209-213, 273. 
 25 Canada, Notice of Arbitration, supra note 2, ¶ 64; Eli Lilly Canada Inc. v. Novopharm 
Ltd., [2012] F.C.A. 232; Eli Lilly Canada Inc., et al. v. Novopharm Ltd., [2013] CanLII 26762 
(SCC). 
 26 Novopharm Ltd. v. Eli Lilly & Co., [2010] F.C. 915 [Can.]. 
 27 Id. ¶ 88. 
 28 Id. ¶ 91-93; Consolboard Inc. v. MacMillan Bloedel (Saskatchewan) Ltd., [1981] 1 
S.C.R. 504, 56 C.P.R. (2d) 145, 524-526 (Can.); Novopharm, supra note 18; Apotex Inc. v. 
Wellcome Foundation Ltd., [2002] SCC 77, 21 C.P.R. (4th) 499, ¶ 70-71 (Can.). 
 29 Id. ¶ 112, 116. 
 30 Id. ¶ 117. 
 31 Id. ¶ 102. 
 32 Id. ¶ 94, 120. 
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disclosed, this is a breach of the public bargain underpinning patentability.33 
Leave to the SCC was denied on December 8, 2011.34 
III. APPLICABLE OBLIGATIONS UNDER NAFTA 
This section summarizes the applicable obligations of the Parties as 
established under NAFTA. First, the standard of treatment as established under 
Article 1105 is provided in conjunction with considerations relating to national 
treatment and most favoured nation (“MFN”) under Articles 1102 and 1103 
respectively. Second, expropriation under Article 1110 is discussed. Lastly, 
issues relating to IP rights as outlined in Articles 1701 and 1709 are summarized. 
The obligations under NAFTA establish a common framework for facilitation 
and regulation of trade based on principles of FET treatment. 
A. Standard of Treatment 
FET is a longstanding pillar of international economic law which has 
become the most frequently invoked standard in investor-state disputes.35 Article 
11 of NAFTA encompasses a collection of obligations relating to investment, 
which applies to investors and investments of another Party occurring in the 
territory of a Party.36 First, each Party is obliged to accord “no less favourable 
treatment” to investors and investments of a foreign Party than is accorded to 
domestic counterparts in like circumstances.37 Second, each Party is obliged to 
provide equivalent treatment to foreign investors and investments as is provided 
in like circumstances to any other nation – Party or non-Party.38 The standards of 
national treatment in Article 1102 and MFN in Article 1103 are intended to 
create an even-handed standard of treatment governing investments made under 
the treaty,39 which provides for no negative legislative or regulatory 
differentiation between foreign and domestic investment and discourages less-
favourable treatment.40 Third, Article 1105 establishes a minimum standard of 
treatment between Parties which ensures Parties are accorded FET and 
“protection and security” in accordance with international law.41 Importantly for 
NAFTA Parties, the customary international legal norm of minimum standard of 
treatment is established as the minimum standard with FET and “protection and 
security” not indicating an increased standard;42 this point provides clarity for 
interpretation of the relevant standard by tribunals.43 
 
 33 Novopharm Ltd. v. Eli Lilly & Co., [2011] FCA 220, ¶ 51. 
 34 Canada, Notice of Arbitration, supra note 2, ¶ 54. 
 35 RUDOLF DOLZER AND CHRISTOPH SCHREUER, PRINCIPLES OF INTERNATIONAL 
INVESTMENT LAW 119 (Oxford University Press, 2nd ed. 2008). 
 36 NAFTA, supra note 1, Article 1101. 
 37 Id. Article 1102. 
 38 Id. Article 1103. 
 39 Id. Article 1104. 
 40 Dolzer & Schreuer, supra note 35, at 178, 186. 
 41 NAFTA, supra note 1, Article 1105(1). [Minimum Standard of Treatment] 
 42 NAFTA Free Trade Commission (FTC) Note of Interpretation (31 July 2001), online: 
Global Affairs Canada. 
 43 Dolzer & Schreuer, supra note 35, at 126. 
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The standards of FET and “protection and security” under both codified and 
customary international law have evolved over time. While broad, the standard 
of FET finds early roots in considerations related to treatment of foreign aliens, 
which was outrageous, in bad faith, or illustrated an insufficiency of government 
reaction which reasonably illustrates an unacceptable departure from 
international standards.44 More recently the standard has been noted to be 
evolving,45 with a focus on a lack of due process and fairness,46 which is 
considered conceptually without the “threshold limitation that the conduct 
complained of be egregious, outrageous, or shocking, or otherwise 
extraordinary.”47 Factors such as transparency, contractual compliance, 
procedural propriety, due process, good faith, and freedom from coercion have 
all been considered by tribunals in the evaluation of the standard of treatment.48 
Additionally, the standard of “protection and security” which initially applied to 
protection from physical threats has been contemporarily interpreted to apply to 
infringements on the rights of the investor through the application of law in the 
host state.49 The focus conceptually has shifted beyond physical considerations to 
centralize generally on access to judicial remedy and diminishment of an 
investment.50 
B. Expropriation 
Expropriation, which sits at the crossroads of sovereignty and respect for 
rights acquired by foreign investors, generally involves interference by the host-
State with a property interest to the detriment of the investor.51 Article 1110(1) 
indicates that Parties are restricted from direct or indirect expropriation, or 
implementation of “measures tantamount to. . . expropriation,” except for a 
public purpose, applied in a non-discriminatory manner, in accordance with due 
process, and with payment of equitable compensation.52 Compensation, which is 
to reflect the fair market value of the investment at the time of expropriation, is 
to be paid “without delay,” and shall be paid in a G7 currency or equivalent.53 
Article 1110(7) indicates explicitly that measures relating to the “issuance, 
 
 44 Neer v Mexico, Opinion, US—Mexico General Claims Commission, 21 AJIL 555 
(1927). 
 45 ADF Group Inc. v USA, ICSID Case No. ARB(AF)/00/1, 18 FILJ 195, ¶ 179 (2003). 
 46 Elettronica Sicula SpA (ELSI) (United States of America v Italy), Judgement, ICJ 
Reports 15 (1989). 
 47 Pope & Talbot v Canada, Award on Merits (Phase 2), 122 ILR 352, ¶ 118 (2002); 
Dolzer & Schreuer, supra note 35, at 129. 
 48 Dolzer & Schreuer, supra note 35, at 133-147; ROLAND KLÄGER, FAIR AND EQUITABLE 
TREATMENT’ IN INTERNATIONAL INVESTMENT LAW 62-74 (Cambridge University Press 2013). 
 49 Dolzer & Schreuer, supra note 35, at 149. 
 50 Id. at 151-152, 162-166; CME v Czech Republic, Partial Award (13 September 2001), 9 
ICSID Reports 121, ¶ 613; Lauder v Czech Republic, Award (3 September 2001), 9 ICSID 
Reports 66, ¶ 314. 
 51 Andrew Newcombe & Lluís Paradell , Law and Practice of Investment Treaties: 
Standards of Treatment, (Netherlands: Kluwer Law International, 2009), at 321 [Newcombe & 
Paradell]; Dolzer & Schreuer, supra note 35 at 89. 
 52 NAFTA, supra note 1, at Article 1110(1). 
 53 Id. Article 1110(2-6); Andrea K Bjorklund, NAFTA Chapter 11, COMMENTARIES ON 
SELECTED MODEL INVESTMENT TREATIES (Oxford University Press, Chester Brown ed. 2013). 
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revocation, limitation, or creation” of IP rights which are consistent with Chapter 
17 are exempted from consideration as expropriation.54 
What amounts to direct or indirect expropriation is a matter of debate and 
divergence, with jurisprudence illustrating the inclusion of legislative, regulatory, 
or administrative actions,55 “regulatory taking” and “creeping expropriation” 
which, through application of law, devalues an investment over time.56 Tribunals 
have focused not just on deliberate actions, such as the revocation of a certificate 
or permit,57 but also on “incidental interference” with the property which, in form 
or effect, neutralizes the economic benefit of the property,58 or deprives the 
owner of a significant part of the “reasonably-to-be-expected economic 
benefit.”59 The standard of “substantial deprivation” in relation to a property 
right resulting in an economic loss has developed as a principal line of inquiry 
when considering indirect expropriation.60 Finally, while the principles of public 
purpose, non-discrimination, due process, and compensation encapsulated in 
Article 1110(1) generally apply, where a non-discriminatory regulation, which 
supports a public purpose, is enacted in accordance with principles of due 
process and not in contravention to previously stated regulatory restraints, such 
normal exercises of regulatory power are suggested to be outside the scope of 
expropriation.61 
C. Intellectual Property 
Obligations relating to IP are addressed in Chapter 17 of NAFTA. Article 
1701(1) establishes framework requirements on NAFTA Parties including: (i) 
providing adequate protection and enforcement of IP rights while ensuring IP 
measures are not trade inhibitors, and (ii) collectively actualizing previously 
established IP Conventions (Geneva 1971, Berne 1971, Paris 1967, and UPOV 
1978, 1991).62 Article 1702 empowers Parties to implement “more extensive” IP 
rights as an alternative, provided these measures remain consistent with the 
Agreement as a whole.63 Article 1703 provides for the application of the 
principle of national treatment to the protection and enforcement of IP rights, 
restricts the implementation of formalities or preconditions to acquisition of IP 
rights (for instance, notice of copyright), and allows for derogation from this 
standard regarding judicial and administrative procedures (such as a requirement 
 
 54 NAFTA, supra note 1, at Article 1110(7). 
 55 JONATHAN BONNITCHA, SUBSTANTIVE PROTECTION UNDER INVESTMENT TREATIES: A 
LEGAL AND ECONOMIC ANALYSIS (Cambridge: Cambridge University Press, 2014), at 231-232; 
Newcombe & Paradell, supra note 51, at 326-327. 
 56 Brown, supra note 53; Newcombe & Paradell, supra note 51, at 324-325. 
 57 Goetz v Burundi, Award, 15 ICSID Review-FILJ 457 (2000) ¶ 124. 
 58 CME v. Czech Republic, supra note 50. 
 59 Metalclad v Mexico, Award, 5 ICSID Reports 209 (2002), ¶ 103. 
 60 Pope & Talbot, supra note 47; Sempra Energy v. Argentina, Award, ICSID Case No. 
ARB/02/16, ¶ 284; Biwater v. Tanzani, Award, ICSID Case No. ARB/05/22 (2008); 
Bonnitcha, supra note 55, at 248-255. 
 61 Methanex v. United States, Final Award (2005) ¶ 1-7; Saluka v. Czech Republic, Partial 
Award (2006) ¶ 255. 
 62 NAFTA, supra note 1, Article 1701(1-2). 
 63 Id. NAFTA, Article 1702. 
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to appoint a domestic agent) provided such derogation is consistent with the 
previously noted IP Conventions.64 
Article 1709 is the principle substantive NAFTA provision relating to 
patents. Article 1709(1) requires Parties to make available patents for “all fields 
of technology,” bearing the invention is “new,” is the result of an “inventive 
step,” and is “capable of industrial application,” with Parties empowered to deem 
“inventive step” and “capable of industrial application” equivalent to “non-
obvious” and “useful.”65 Article 1709(2) and (3) provide for exceptions to the 
minimum standard of patentability, particularly allowing Parties to exclude from 
patentability inventions which pose a serious harm to life, health or the 
environment (public order exception), as well as: surgical methods, non-
microbial plants and animals, and biological processes for the production of non-
microbial plants and animals.66 Parties are further required to: (i) provide for 
patent protection for pharmaceuticals, chemicals, and agricultural products no 
later than January 1, 1992,67 (ii) ensure that the acquisition of a patent provides 
for exclusive rights relating to the product or process, with the option to provide 
limited exceptions to such exclusive rights provided they are not unreasonably 
prejudicial,68 and (iii) ensure patent rights may be exercised in a non-
discriminatory manner with relation to the field, or geographic location for 
production of the technology.69 
Article 1709(8) indicates that Parties may only revoke a patent where 
“grounds exist that would have justified a refusal to grant the patent,” or where 
the issuance of a compulsory license has not remedied a lack of commercial 
exploitation.70 Parties shall also permit the assignment, license, and transfer of 
patents, integrate minimum patent-use authorization standards, place on the 
defendant the onus in claims of product process infringement, and provide a 
protection term of at minimum twenty years from the filing date, or seventeen 
years from the grant date.71 It is also important to note that domestic enforcement 
procedures relating to IP rights are available, and are required to be fair and 
equitable, not unnecessarily cumbersome, costly or complicated, with domestic 
adjudication based on the merits of the case in line with principles of due process 
and subject to appeal.72 
 
 64 Id. NAFTA, Article 1703; Dorothy Schrader, Intellectual Property Provisions of the 
NAFTA, Congressional Research Service: Report to Congress 94-59A (21 January 1994), at 
3-4. 
 65 Id. Article 1709(1). 
 66 Id. Article 1709(2-3). 
 67 Id. Article 1709(4). 
 68 Id. Article 1709(5-6). 
 69 Id. Article 1709(7). 
 70 Id. Article 1709(8). 
 71 Id. Article 1709(9-12). 
 72 Id. Article 1714(2-4), 1715(1). 
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IV. PATENT STANDARDS ACROSS NAFTA JURISDICTIONS 
This section provides a discussion of the standards of patentability across 
NAFTA jurisdictions, with a focus on the promise utility doctrine and sound 
prediction. First, the theoretical background, legislative underpinning, and 
applicable jurisprudence relating to the promise utility doctrine in Canada is 
outlined. Second, patent standards in the United States are summarized, with an 
emphasis on highlighting the “enablement” and “written description” doctrines. 
Finally, patent standards applied in Mexico are briefly provided to illustrate 
similarities and differences across NAFTA. The promise utility doctrine, as 
developed in Canadian jurisprudence, is a unified articulation of core principles 
relating to patent scope, adequacy of disclosure, and timing of patent, which, 
while procedurally differentiated across NAFTA jurisdictions, goes to the heart 
of the patent bargain applied by all Parties when considered in relation to 
speculative patent practices. 
A. Patent Law of Canada and the Patent Utility Doctrine 
Patent protection, which in Canada is governed exclusively by the Patents 
Act,73 is grounded in an essential bargain between the Crown and the inventor 
based on adequate public disclosure of a “novel,” “unobvious,” and “useful” 
invention in exchange for a term-limited monopoly intended to incentivize 
innovation.74 Under the Patents Act, the invention in question must be a 
patentable subject-matter, be new, non-obvious, useful, and accompanied by 
sufficient disclosure in the patent itself.75 Patentable subject matter relates to “all 
fields of technology,” a notion encompassed in the Section 2 definition of 
“invention,” which includes “any new and useful art, process, machine, 
manufacture or composition of matter,” or an improvement to a previous 
patent,76 including new uses of previously known compounds.77 An invention is 
required to be new,78 and not anticipated by a single reference of prior art.79 
Section 28.3 requires that the invention be non-obvious to a “person skilled in 
the art” on the date of claim.80 Utility or “usefulness” which must be 
demonstrated or soundly predicted at the claim date,81 is a further factor in the 
requirement for sufficient disclosure in the patent under Section 27(3), which 
 
 73 Canada, Patents Act (1985), P-4. 
 74 STEPHEN J. PERRY & T. ANDREW CURRIER, CANADIAN PATENT LAW (Markham, Ontario: 
LexisNexis, 2nd ed. 2014), at 39; ELIZABETH JUDGE & DANIEL GERVAIS, INTELLECTUAL 
PROPERTY: THE LAW IN CANADA (Toronto, Canada: Carswell, 2nd ed. 2011) at 643-646; AZT, 
supra note 28, ¶ 37; Pioneer Hi-Bred Ltd. v. Canada (Commissioner of Patents), [1989] 1 
S.C.R., 1623, 60 D.L.R. (4th)223, 25 C.P.R.(3d) 257, 97 N.R. 185 (S.C.C.) ¶ 25; Sanofi-
Aventis v. Apotex Inc., [2009] F.C.J. No. 986 ¶ 358, 2009 FC 676 (F.C.), affd [2011] F.C.J. 
No 1532, 2011 FCA 300 (F.C.A.) leave to appeal refused [2012] S.C.C.A. No. 19 (S.C.C.). 
 75 Canada Patents Act, supra note 73, § 2, 27(3), 27(8), 28.2(1), 28.3. 
 76 Id. § 2, 32. 
 77 Shell Oil Co. v. Canada (Patent Commissioner) [1982] 2 S.C.R. 536, ¶ 30-34. 
 78 Canada Patents Act, supra note 73, § 2, 28.1, 28.2. 
 79 Id. § 28.3. 
 80 Id. 
 81 AZT, supra note 28, ¶ 52. 
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requires that disclosure describe the invention in such detail and clear terms as to 
empower a person skilled in the art to bring about the desired effect.82 It is the 
convergence of utility, sound prediction, and sufficient disclosure which brought 
to light the patent utility doctrine. 
The exclusive rights encapsulated in a patent are not absolute, but are subject 
to satisfaction of the terms of the Patents Act and are reviewable and revocable 
through judicial interpretation at the Federal Court.83 Patent utility has two core 
dimensions: first, the invention must provide something of commercial value, 
and second, the invention must be operable based on sufficient disclosure 
allowing a person skilled in the art to bring about the desired promise of the 
patent.84 Where no specific promised result is made in the specification, a “mere 
scintilla” of utility is sufficient, but where a promised result is provided, utility 
must be considered by this measure.85 The weighing of a patent’s utility against a 
promise made in the specifications, a question of claim construction which 
substantively underpins the promise utility doctrine, is an inquiry wedded to the 
historical and theoretical justifications of the patent bargain.86 Being imported 
from the English tradition, the promise utility doctrine has a longstanding judicial 
history in Canada,87 with early authorities New Process Screw, Consolboard and 
X. v. Canada (Patent Commissioner) stressing a focus not on an assessment of 
the marketable value of the invention, but on the sufficiency of disclosure to 
bring about the promised outcome.88 Early jurisprudence also illustrates the 
importance of a balanced scope to patent claims, with speculative or unachieved 
claims risking invalidation of the patent as a whole.89 The principal question is 
whether a person skilled in the art, equipped with the disclosed specifications, 
can produce the invention.90 More recent articulations in Teva Canada Ltd. v. 
Pfizer Canada Inc. and the aforementioned Eli Lilly and Novopharm saga 
reemphasized the well-established principle that patents, to have utility, must 
attain their implicit and explicit promises.91 
 
 82 Canada Patents Act, supra note 73, § 27(3). 
 83 Id. § 42, 60(1). 
 84 Judge & Gervais, supra note 74, at 724; Eli Lilly & Co. v. Canada, Expert Report of 
Ronald E. Dimock (26 January 2015) ¶ 66-67. 
 85 Laboratoires Servier v. Apotex Inc. [2008] F.C.J. No 1094, 2008 FC 825, ¶ 270; 
Consolboard, supra note 22. 
 86 Perry & Currier, supra note 74, at 141; Eli Lilly, supra note 18, ¶ 80; Consolboard , 
supra note 22, ¶ 32; Tubes, Ld. v Perfecta Seamless Tube Company, Ld. (1902), 20 RPC 77. 
 87 HALSBURY’S LAWS OF ENGLAND, vol. 29 (United Kingdom: Butterworth & Co, 3rd ed. 
1960) at 59; Consolboard , supra note 22; Eli Lilly & Co. v. Canada, Government of Canada 
Counter Memorial ¶ 103 (2015); HAROLD G. FOX, CANADIAN PATENT LAW AND PRACTICE 
(Toronto: Carswell, 4th ed. 1969), at 153: “It is, therefore of the utmost importance to decide 
whether the specification makes a promise of a result and whether the ordinary workman 
would understand that that particular result is promised.” 
 88 Judge & Gervais, supra note 74, at 724-725; Consolboard , supra note 22, ¶ 36-37, 271-
272; X. v. Canada (Patent Commissioner) (1981), 59 C.P.R. (2d) 7 46 N.R. 407, ¶ 4; New 
Process Screw Corp. v. PL Robertson Mfg Co. Ltd., (1961), 39 CPR 31 (Ex Ct), ¶ 33-34. 
 89 Amfac Foods Inc. v. Irving Pulp & Paper, Ltd., (1986), 12 CPR (3d) 193 (FCA); 
Dimock Report, supra note 84, ¶ 75-81. 
 90 Pioneer Hi-Bred Ltd. v. Canada (Commissioner of Patents), [1989] 1 SCR 1623. 
 91 Teva Canada Ltd. v. Pfizer Canada Inc., [2012] 3 SCR 625. 
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Utility must further be demonstrated or soundly predicted by the filing 
date.92 The doctrine of sound prediction, which evolved in reply to patents for 
broad classes of compounds with only isolated testing, allows for patent utility to 
be asserted based on a factual basis and articulated line of reasoning which 
would empower a person skilled in the art to recognize the prediction as sound.93 
The three pillars of the doctrine of sound prediction were articulated in AZT to 
include: (i) a factual basis for the prediction, (ii) an “articulated” and “sound” 
line of reasoning as of the patent filing date, and (iii) proper disclosure.94 
Speculation, even if eventually fulfilled, is not sufficient to satisfy the patent 
bargain, as the public would be excluded from innovating while not gaining 
anything further than a hypothesis.95 The doctrine of sound prediction is also 
highly dependent upon sufficient disclosure, with both the factual evidence and 
the line of reasoning supporting the prediction to be included.96 Regarding the 
sufficiency of evidence to support the prediction, Eurocopter, relating to a 
mechanical invention, held that while testing of all variations is not needed, 
disclosure of some test data supporting the claimed configuration or composition 
is sufficient, bearing the evidence is not speculative but supports the production 
of the specific advantages.97 Relating to the interface of pharmaceutical 
disclosure and sound prediction, Pfizer Canada v. Mylan Pharmaceuticals ULC 
citing AZT held that prior human trials relating to toxicity were not needed, 
noting the inquiry relates to utility not safety, and highlighting that sound 
prediction inherently indicates that “further work remains to be done.”98 Where a 
sound prediction in a selection patent is made, proposed advantages must be 
supported by sufficient evidence disclosed prior to the filing date,99 with such 
evidence being tested in relation to the original group suggested to be 
sufficient.100 Simply put, where a patent is based on a sound prediction, there is 
an increased emphasis on sufficient disclosure, and the prediction must be 
included in the description section of the patent,101 so as to provide a solid 
teaching in exchange for the right to patent the invention.102 The promise utility 
doctrine only applies where there is a “clear and unambiguous promise” in the 
patent.103 
 
 92 AZT, supra note 28, ¶ 52, 56. 
 93 Dimock Report, supra note 84, ¶ 98-100; Monsanto Company v. Commissioner of 
Patents, [1979] 2 SCR at 1108. 
 94 AZT, supra note 28, ¶ 70; Judge & Gervais, supra note 74, at 728. 
 95 Id. ¶ 84. 
 96 Eli Lilly Canada Inc. v. Apotex Inc., [2008] F.C.J. No. 171, 2008 FC 142 (F.C.); Eli 
Lilly and Co v. Teva Canada Ltd, [2010] F.C.J. No 1115, ¶ 117. 
 97 Eurocopter v. Bell Helicopter Textron Canada Ltée, [2012] F.C.J. No. 107, 2012 FC 
113, ¶ 354, 368. 
 98 Pfizer Canada Inc. v. Mylan Pharmaceuticals ULC, [2012] F.C.J. No. 386, 2012 FCA 
103, ¶ 53-54. 
 99 Eli Lilly, supra note 20, ¶ 210. 
 100 Apotex Inc. v. H. Lundbeck A/S, [2013] F.C.J. No. 274,2013 FC 192. 
 101 Eli Lilly Canada Inc. v. Apotex Inc., [2009] F.C.J. No. 404, 2009 FCA 97, ¶ 14-15; 
Pfizer Canada Inc. v. Pharmsciences Inc., [2013] F.C.J. No.11, 2013 FC 120, ¶ 102-105. 
 102 AZT, supra note 28, ¶ 69. 
 103 Apotex Inc. v. Pfizer Canada Inc., [2014] FCA 250. 
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B. Patent Law of the United States and the Enablement and Written Description 
Doctrines 
American patent law is governed through Chapter 35 of the United States 
Code.104 A list of patentable subject matter – nearly identical to the s.2 definition 
of “invention” in Canada – is included in the §100 definition of “process,” with 
patentable inventions identified in §101 as “any new and useful process, 
machine, manufacture or composition of matter. . . or improvement thereof.”105 
Novelty, as set out in §102 must be satisfied, requiring the patented subject 
matter not to be previously patented, described in a publication, or publicly 
available, with a one-year grace period provided negating prior disclosure made 
by the inventor equating to prior art or anticipation.106 Recent reforms have also 
implemented a “first to file” model bringing the U.S. practice in-line with 
international practice.107 As per §103 the patented invention must also be non-
obvious to a person skilled in the art.108 While the notion of utility is 
encapsulated in “useful” under §101, American jurisprudence has elaborated 
three distinct criteria: (i) the invention must provide credible utility to a person 
skilled in the art (operability),109 (ii) the utility in question must be specific in 
nature (specific) and (iii) provide a substantial or practical benefit.110 
This bifurcated approach assesses not just utility, in as much as the invention 
must have a specific use, but also operability, in as much as the invention must 
be capable of achieving the benefit of the patent.111 A patent must include an 
“assertion of utility,”112 a notion comparable to a promise in Canadian 
jurisprudence, well-described in non-generic and specific language,113 which at 
the time of filing is grounded in sufficient data supporting the desired results of 
the invention.114 As set out in §112(a), patent specification shall contain “a 
written description of the invention,” which must clearly enable a person skilled 
in the art to “make and use” the claimed invention, including guidance on the 
 
 104 United States, Chapter 35, United States Code (as amended 2012) [35 U.S.C.]. 
 105 Id. §100-101. 
 106 Id. §102(a-b). 
 107 United States, Act To Correct and Improve Certain Provisions of the Leahy-Smith 
America Invents Act and Title 35, United States Code, HR 6621 (Public Law No.112-274, 126 
Stat. 2456). 
 108 35 U.S.C., supra note 104, §103. 
 109 Process Control Corp. v. HydReclaim Corp., United States Court of Appeals, Federal 
Circuit, 190 F.3d 1350, 1358, 52 USPQ2d 1029, at 1034 (Fed. Cir. 1999); In re Mitchell R. 
Swartz, United States Court of Appeals, Federal Circuit, 232 F.3d 862 (Fed. Cir. 2000), at 1-2. 
 110 In re Fisher, United States Court of Appeals, Federal Circuit, 421 F.3d 1365 (Fed. Cir. 
2005), at 9-10; Eli Lilly & Co. v. Canada, Expert Report of Timothy R. Holbrook (26 January 
2015), ¶ 20. 
 111 E. Richard Gold & Michael Shortt, The Promise of the Patent in Canada and Around the 
World, 30:1 
Canadian Intellectual Property Review 35, (2014), at 32-33. 
 112 In re Bremner, 182 F.2d 216 at 216(CCPA 1950); In re Fisher, supra note 110, at 10-11. 
 113 In re Kirk, 376 F.2d 936, (C.C.P.A. 1967), at 941. 
 114 Cre-Agri, Inc. v. Pinnaclife, Inc., No.: 11-CV-6635-LHK, 2013 WL 6673676, at 16 
(N.D. Cal. Dec. 18, 2013); Rasmusson v. SmithKline Beecham Corp., 413 F.3d 1318, 1325 
(Fed. Cir.2005). 
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best mode contemplated for the invention, and shall include one or more specific 
claims distinctly illustrating the subject-matter of the invention.115 The 
enablement doctrine articulated in the §112 requirement of “written description” 
is equitable to sufficient description obligations in Canada,116 and serves a dual 
purpose, of “ensuring adequate disclosure” and dissuading overly broad claims 
or “invention without experimentation.”117 While the promise utility doctrine 
remains a construct of the Anglo-Canadian tradition, significant substantive 
alignment can be found in the American approaches relating to the “written 
disclosure,” “operability,” “enablement,” and “assertion of utility” doctrines.118 
C. Patent Law of Mexico 
Mexico, whose domestic IP system underwent significant reform in 2010,119 
approaches utility through the doctrine of “industrial application.”120 An 
invention, characterized as any human creation which transforms energy or 
matter to address a concrete need,121 is required to be new, involve an “inventive 
activity” and be capable of industrial application.122 Novelty and non-
obviousness are assessed in relation to the state of the art on the filing date, with 
a one-year grace period provided for patenting.123 As per Article 12, the patent 
must include a written description of: (i) everything new which is contributed to 
the state of the art, (ii) the current state of the art, (iii) the creative process which 
is non-obvious to a person skilled in the art, (iv) the practical utility or use in 
commerce, and (v) the claimed essential characteristics.124 Article 47 stresses that 
the description needs sufficient clarity and comprehensiveness to enable a full 
understanding and actualization of the invention by a person skilled in the art, 
including best-known methods of execution, and underlying information 
establishing the industrial applicability.125 Additional information may also be 
requested or required by patent authority to support any information provided in 
the patent application during the processing.126 Insufficient disclosure or 
“descriptive insufficiency” is seen as synonymous with “lack industrial 
applicability,” but admittedly these concepts are underdeveloped.127 
 
 115 35 U.S.C., supra note 104, at §112(a-b); Cre-Agri, supra note 114; Ariad Pharm., Inc. 
v. Eli Lilly & Co., 598 F.3d 1336, 1351 (Fed. Cir. 2010). 
 116 Gold & Shortt, supra note 111, at 35. 
 117 Id.; MagSil Corp. v. Hitachi Global Storage Techs., Inc., 687 F.3d 1377, No. 2011–
1221 (2012; Holbrook Report, supra note 110, at 17. 
 118 Gold & Shortt, supra note 111, at 38-40; Holbrook Report, supra note 110, ¶ 6. 
 119 Eli Lilly & Co. v. Canada, Expert Report of Hedwig Lindner (26 January 2015), ¶ 27. 
 120 Industrial Property Act, Official Diary of the Federation of June 27, 1991, (Last 
Reform, Official Diary of the Federation of April 9, 2012), at Article 16; unofficial translation 
of Ley de la Propiedad Industrial, Diario Oficial de la Federación el 27 de junio de 1991, 
(Última reforma publicada DOF 09-04-2012) [Industrial Property Act]. 
 121 Id. Article 15. 
 122 Id. Article 16. 
 123 Id. Article 17-18. 
 124 Id. Article 12. 
 125 Id. Article 47. 
 126 Id. Article 55. 
 127 Lindner Report, supra note 119, ¶ 82. 
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V. COMPATIBILITY OF THE PROMISE UTILITY DOCTRINE AND OBLIGATIONS 
UNDER NAFTA 
This section will evaluate the consistency of the promise utility doctrine with 
NAFTA obligations as seen in the cases of Zyprexa (olanzapine) and Strattera 
(atomoxetine). Three key questions will be discussed: (i) if the promise utility 
doctrine denies treatment guaranteed under the minimum standard of treatment; 
(ii) if the application of the promise utility doctrine results in direct or indirect 
expropriation; (iii) if the promise utility doctrine is incompatible with the 
established IP norms. First, the reasonably expected standard of treatment under 
Article 1102, 1103, 1105, and 1703 is considered. Second, an inquiry of 
expropriation under Article 1110 is provided. Lastly, the promise utility doctrine 
is reviewed in relation to international IP norms and subsequent alignment with 
Article 1709. The promise utility doctrine is an evolutionary articulation of 
longstanding NAFTA compliant IP principles driven by an enhanced need for 
enforcement of adequate disclosure standards to maintain the patent bargain in a 
new and rapidly developing age of innovation. 
A. An Inquiry into the Standard of Treatment 
In evaluating the standard of treatment under Article 1105, core principles of 
consideration are FET and “legitimate expectations.”128 Regarding the former, in 
Waste Management II it was noted that Article 1105 does not create an open-
ended review mechanism;129 rather the focus remains on egregious conduct or 
lack of due process, with the tribunal suggesting the FET principle is violated in 
cases of state conduct which is “arbitrary, grossly unfair . . . [or] lack[s] due 
process.”130 Where there is a denial of justice, a systemic analysis is often 
conducted,131 as illustrated in Metalclad (refusal by a municipal authority to issue 
construction permit), Tecmed (revocation of a license to operate), Loewen 
(propriety of court proceedings), and Petrobart (state intervention in the 
execution of a judgment).132 As noted in BilCon, the categorical formula put 
forward in Waste Management while “particularly apt” also conveys a high 
threshold of conduct to equate to a breach of Article 1105.133 The national 
treatment and most favorable nation standards grounded in Article 1102 and 
 
 128 Bonnitcha, supra note 55, at 147, 152-153. 
 129 Waste Management Inc. v. United Mexican States (“Number 2”), Award, ICSID 
ARB(AF)/00/3, ¶ 94-98 (2004); S.D. Myers, Inc. v. Government of Canada, (UNCITRAL), 
Partial Award ¶ 261, 263 (2000). 
 130 Waste Management II, supra note 129, ¶ 94-98; The Loewen Group, Inc. and Raymond 
L. Loewen v. United States of America, Award (Case No. ARB (AF)/98/3) ¶ 124-126 (2003). 
 131 Waste Management II, supra note 129, ¶ 97. 
 132 Dolzer & Schreuer, supra note 35, at 142-144; Metalclad, supra note 59; Tecmed v 
Mexico, No. ARB (AF)/002, at 133 (2003); Loewen, supra note 130; Petrobart v Kyrgyz 
Republic, Award, SCC Case No. 126/2003 (2005). 
 133 William Ralph Clayton, William Richard Clayton, Douglas Clayton, Daniel Clayton 
and Bilcon of Delaware Inc v. Government of Canada, Award on Jurisdiction and Liability, 
PCA 2009-04 ¶ 443-444 (2015). 
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1103 respectively, also incorporate factors such as “like circumstances,” and if 
the measure places a foreign investment at a “disproportionate disadvantage.”134 
The judicial invalidations of patent 113 relating to Zyprexa (olanzapine) and 
patent 735 relating to Strattera (atomoxetine) were made in accordance with the 
standards of FET and national treatment. While Eli Lilly claim the 113 and 735 
patent decisions specifically, and the underlying jurisprudence supporting the 
promise utility doctrine more broadly, are “improper and discreditable,”135 I find 
this position difficult to support. In both cases, Eli Lilly received fair and 
impartial protection and treatment under the law, with transparent and 
substantively sound forums for due process. As noted in Mondev, when 
considering judicial decisions, the test is not if the result was “surprising,” but if 
the result calls into question the “juridical propriety” of the decision, with 
international tribunals explicitly recognized as “not courts of appeal.”136 An 
Article 1105 inquiry is concerned with identification of a denial of justice, 
discrimination,137 or arbitrariness in the judicial process,138 rather than providing 
a substantive review of valid decisions made by domestic authorities.139 The 
invalidation of the 113 and 735 patents were grounded in longstanding legal 
principles established far prior to the establishment of NAFTA.140 If, as noted in 
Bilcon, the investor can expect, absent any changes in domestic law, to have a 
case assessed on the “merits,” based on the “same legal standards applied to 
applicant[s] generally,” then indeed Eli Lilly did receive their legitimate 
expectations of a sound legal framework and developed patent law, contrary to 
their assertion.141 The 113 and 735 patents simply failed on their merits, which is 
not a valid violation of the principle of FET. Deference must always be paid to 
domestic courts in the determination of property and application of interpretive 
techniques unless such action calls into question the judicial propriety of the 
system. 
B. An Inquiry into the Expropriation 
When considering under Article 1110 if a measure is, or is tantamount to, 
expropriation directly or indirectly, tribunals have taken differing approaches: (i) 
looking “exclusively” at the effects of the measure to the investment in question 
(Metalclad, Pope & Talbot), (ii) looking at the effects more broadly, subject to 
outlined exceptions (Methanex), and (iii) a balancing approach which considers 
both the effects and the characteristics of the measure (Feldman).142 
Conceptually, direct and indirect expropriation are often differentiated on the 
 
 134 Pope & Talbot, supra note 47, ¶ 43. 
 135 Canada, Notice of Arbitration, supra note 2, ¶ 81. 
 136 Mondev International Ltd. v. United States of America, Award, ICSID Case No. ARB 
(AF)/99/2, ¶ 127 (2012). 
 137 Waste Management II, supra note 129, ¶ 129-130; Loewen, supra note 130. 
 138 ELSI, supra note 46, ¶ 128. 
 139 Mondev, supra note 136, ¶ 133. 
 140 Consolboard, supra note 22. 
 141 Notice of Arbitration, supra note 2, ¶ 82. 
 142 Bonnitcha, supra note 55, at 230. 
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grounds of the impact of the measure on the legal title of the investment,143 with 
the phrases “tantamount to expropriation” interpreted as equating to indirect 
expropriation.144 An “investment” for the purposes of Article 1110(1) includes 
legitimately acquired property interests – both tangible and intangible.145 
Two distinct lines of inquiry relating to the influence of the “effects” of 
indirect expropriation exist, exemplified by Metalclad and Pope & Talbot 
respectively.146 In Metalclad, where denial of a municipal construction permit 
and passing by the state of an “Ecological Decree” inhibited operation of a 
proposed hazardous waste landfill, the tribunal defined expropriation to include 
“covert or incidental interference” with a property interest which deprives the 
investor “in whole or significant part” of the “reasonably-to-be-expected 
economic benefit” of the property.147 Subsequent decisions in Occidental v. 
Ecuador (II), and Chemtura v. Canada have somewhat distanced themselves 
from the “broad definition” applied in Metalclad, adopting without application 
the standard.148 An alternative approach was applied in Pope & Talbot, where an 
export quota on softwood lumber was set in place, with the tribunal classifying 
the ability to export the product as an independent property interest from the 
business as a whole,149 with expropriation of that property interest required to be 
a “substantial deprivation.”150 The standard of “substantial deprivation” has been 
endorsed in Fireman’s Fund and Chemtura,151 albeit prior to a balancing 
exercise.152 Subsequent applications of the Pope & Talbot standard have 
highlighted various practices which amount to indirect expropriation, including 
notably, deprivation of control over the investment, or deprivation of property in 
whole or in part,153 and noted the need for the substantial interference to actually 
cause economic harm154 and involve deprivation of all or a significant part of the 
property interest.155 
An exception to the general rule against expropriation was established in 
Methanex, where an environmentally focused regulatory scheme was upheld on 
the grounds that a “non-discriminatory regulation for a public purpose,” 
implemented in accordance with principles of due process and previous 
 
 143 Dolzer & Schreuer, supra note 35, at 92. 
 144 Pope & Talbot v. Canada, Interim Award, 26 June 2000, ¶ 96; Feldman v. Mexico, 
Award, ICSID Case No. ARB(AF)/99/1, ¶ 100 (2002); SD Myers v. Canada, supra note 129, ¶ 
286; Waste Management II, supra note 129, ¶ 155. 
 145 NAFTA, supra note 1, Article 1139. 
 146 Bonnitcha, supra note 55, at 247; Chemtura v. Canada, (2 August 2010) ¶ 249. 
 147 Metalclad, supra note 59, ¶ 103. 
 148 Chemtura, supra note 146, ¶ 248; Occidental v. Ecuador (I), Final Award, UN No. 3467 
¶ 87-88 (2004). 
 149 Pope & Talbot Interim Award, supra note 144, ¶ 4, 98. 
 150 Id. ¶ 102. 
 151 Chemtura, supra note 146 at para 249; Fireman’s Fund v. Mexico, Award, 17 July 
2006, ICSID Case No. ARB (AF)/02/1, ¶ 176. 
 152 Bonnitcha, supra note 55, at 251-252. 
 153 Sempra Energy, supra note 60, ¶ 284. 
 154 Bayindir v. Pakistan, Award, ICSID Case No. ARB/03/29, ¶ 458-460 (2009). 
 155 Grand River Enterprises Six Nations Ltd. et al. v. United States, Award, ¶ 151 (2011); 
Bosh v. Ukraine, Award, ICSID Case No. ARB/08/11, ¶ 210 (2012). 
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international commitments, was not deemed expropriation.156 Similarly, in 
Saluka enforcement of banking regulations resulting in liquidation of the 
investment was upheld as a valid exercise of regulatory authority “aimed at the 
general welfare.”157 Subsequent tribunals have applied the requirements of public 
policy and due process from Methanex to cases involving cancelation of a tariff 
index framework, and cancelation of an operation permit, under the “police 
powers” exception for valid exercises of domestic authority.158 A further 
approach was adopted by the tribunal in Tecmed, where cancelation of a license 
to operate after a year of operation was deemed to be indirect expropriation on 
the grounds of reasonable expectations, and rejecting a broad exception, 
alternatively indicated the need for proportionality between the measure and the 
aim sought.159 Likewise, in Azurix and LG&E the tribunal reiterated the general 
welfare exception requiring the measure not be “obliviously disproportionate to 
the need being addressed.”160 Finally, in Feldman v. Mexico the principal 
question pertained to if the measure was a valid governmental activity; the 
tribunal taking a holistic view of the circumstance, balanced the character and 
effects of the measure and considered: (i) the general nature of the measure, (ii) 
the rational public purpose, (iii) the deprivation of rights, and (iv) retention of 
control of the investment.161 
The judicial invalidations of patent 113 and patent 735 were not 
expropriation of a valid property interest under Article 1110(1). First, the 
invalidation of the aforementioned patents through application of the promise 
utility doctrine extinguished the validity of the property interest for the purposes 
of Article 1139 and 1110(1), as only domestic law may determine the validity of 
a property interest.162 Second, application of the promise utility doctrine did not 
amount to a substantial deprivation under Pope & Talbot. While the judicial 
proceedings resulted in the patents being invalidated, Eli Lilly had enjoyed their 
exclusive rights for nearly the full term, still retained the ability to sell the 
products, albeit at a reduced margin of sale, and still retained a highly successful 
enterprise with a wide spectrum of financial and property interests. The 
aforementioned patents were only two in a stable of IP interests by Eli Lilly, the 
depth, breadth, or value of which was not substantially diminished. Looking at 
substantial deprivation holistically as was done in Feldman, the enforcement of 
patent rights serves as a valid public purpose, with invalidation being the sole 
proportionate outcome. Maintenance of the patent bargain by way of requiring 
 
 156 Methanex, supra note 61, ¶ 7–15. 
 157 Saluka, supra note 61, ¶ 255. 
 158 AWG Group v. Argentina, Decision on Liability, ICSID No. ARB/03/19, ¶ 140 (2010); 
Chemtura, supra note 146, ¶ 266; Bonnitcha, supra note 55, at 257-259. 
 159 Tecmed, supra note 132, ¶ 116, 119-122. 
 160 Azurix v. Argentina, Award, ICSID Case No.ARB/01/12, ¶ 316 (2006); LG&E Energy 
v. Argentina, Decision on Liability, ICSID Case No. ARB/02/01, ¶ 195, 200 (2006). 
 161 Feldman, supra note 144, ¶ 111-116, 136-137. 
 162 Emmis International Holding, B.V. Emmis Radio Operationg, B.V. Mem Magyar 
Electronic Media Kereskedelmi Es Szolgaltato KT v. Hungary, Award, ICSID Case No. 
ARB/12/2, ¶ 161-162 (2014); EnCana Corporation v. Republic of Ecuador, (UNCITRAL) 
Award, LCIA Case No. UN3481, ¶ 184 (2006). 
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the patent to achieve the claimed end, ensures the public is provided with 
adequate instructions to achieve the benefit of the invention in return for the term 
limited monopoly, and is vital to guaranteeing that innovation remains enabled to 
develop and build upon the prior art. Finally, if presumptively expropriation 
prima facie could be found, the actions relating to the 113 and 735 patents are 
valid exceptions under the Methanex, Saluka, Azurix and LG&E “police powers 
doctrine.” The promise utility doctrine is a non-discriminatory application of 
legislation, in accordance with due process and prior international commitments, 
and in support of an integral public purpose – upholding the patent bargain. 
C. An Inquiry into Intellectual Property 
When assessing the exemption of measures relating to the issuance or 
revocation of IP rights under Article 1110(7), alignment of the measure with 
obligations under Article 1709(1) and 1709(7-8) is a principal area of focus. 
First, Article 1709(1) contains substantively equivalent language to TRIPS 
Article 27(1),163 requiring patents be allowed in “all fields of technology” 
bearing they are “new,” involve an “inventive step,” and are “capable of 
industrial application,” with “inventive step” and “capable of industrial 
application” synonymous with “non-obvious” and “useful.” These notions are 
each integrated into the domestic legislation of NAFTA Parties through the 
definitions of “invention” in Canada,164 “process” in the United States,165 and 
“industrial application” in Mexico.166 Additionally, the explicit reference that 
“inventive step” and “capable of industrial application” are equivalent to “non-
obvious” and “useful,”167 implicitly imports a recognition of the parallel legal 
traditions and subsequent differential jurisprudence. 
Second, Article 1709(7) prohibits patent discrimination on the grounds of the 
type of technology, or place of production. While it is claimed that 
pharmaceutical patents are disproportionately targeted,168 as a component of the 
Common Law, in actuality the promise utility doctrine is applied across all 
patents regardless of technology, and has been utilized in consideration of both 
mechanical and chemical patents.169 Any disproportionality in form or effect is a 
result of the endemic nature of speculative and overly broad patent practices in 
the pharmaceutical industry generally.170 Third, Article 1709(8) provides that a 
patent may be revoked where grounds exist which would have justified refusal 
for the patent to be granted. Illustrating the alignment of the promise utility 
 
 163 Marrakesh Agreement Establishing the World Trade Organization, 15 April 1994, 
UNTS Volume 1867, No 31874, Annex 1C: Agreement on Trade-Related Aspects of 
Intellectual Property Rights, Article 27(1). 
 164 Canada Patents Act, supra note 73, s. 2, 28. 
 165 35 U.S.C., supra note 104, §100-101. 
 166 Mexico Industrial Property Act, supra note 120, Article 16. 
 167 NAFTA, supra note 1, at Article 1709(1). 
 168 Canada, Claimants Memorial, supra note 6, ¶ 186. 
 169 Eurocopter, supra note 97; New Process Screw, supra note 88; Dow Chemical 
Company v. NOVA Chemicals Corporation, [2014] FC 844. 
 170 Ikechi Mgbeoji and Byron Allen, Patent First, Litigate Later! The Scramble for 
Speculative and Overly Broad Genetic Patents: Implications for Access to Health Care and 
Biomedical Research, 2 CANADIAN JOURNAL OF LAW AND TECHNOLOGY 2, 83-98 (2003). 
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doctrine, the utility of an invention as noted in AZT must be demonstrated or 
soundly predicted by the filing date, based on a sound line of reasoning, or the 
patent would be “offering nothing to the public but wishful thinking.”171 
Fourth, some divergence in the legislative implementation of international IP 
standards is tolerated under international law,172 with the independence of patent 
jurisdictions reinforced in Article 4bis of the Paris Convention.173 As seen in 
Harvard Mouse, where a method patent was allowed but the patent on the higher 
life form rejected on the interpretation of “invention” in contrast to other 
jurisdictions, while global trade makes it desirable for differing IP jurisdictions 
to come to “similar legal results,” it is important to allow for statutory 
interpretation based on the purpose of the Act contextualized by key public 
policy concerns, which at times brings about divergent results.174 The utility 
standard as applied in Canada, under the promise utility doctrine, and in the 
United States, under the doctrines of “enablement” and “written description,” 
achieve technically and substantively similar results through enforcing differing 
aspects of the patent bargain.175 
Fifth, while substantively similar, the divergence between the Canadian and 
U.S. approaches to utility is procedural in nature.176 Under the U.S. system, once 
the patent holder proves an infringement has occurred, the infringing party is 
estopped from questioning the utility of the invention, leaving utility and patent 
bargain inquiries practically occurring under the doctrines of “written 
disclosure,” “operability,” “enablement,” and “assertion of utility.”177 
Sixth, the uniform substantive principles applied across NAFTA 
jurisdictions aim to address an important public policy concern – the prevention 
of speculative patents – with each jurisdiction’s judiciary placing emphasis on 
differing operative elements of the domestic patent framework. On utility the 
NAFTA jurisdictions have developed a common-but-differentiated approach on 
utility where Canada utilizes the promise utility doctrine coupled with sound 
prediction,178 the United States cites operability, enablement and written 
description doctrines,179 and Mexico views “descriptive insufficiency” as 
 
 171 AZT, supra note 28, ¶ 52, 56. 
 172 D. HALJAN, SEPARATING POWERS: INTERNATIONAL LAW BEFORE NATIONAL COURTS, at 
31-61, 73-79 (Netherlands: Springer, 2013); Eli Lilly & Co. v. Canada, Second Expert Report 
of Dr. Daniel Gervais, ¶ 11-12 (7 December 2015). 
 173 Paris Convention on the Protection of Industrial Property, (signed 20 March 1883, as 
amended 1979), at Article 4bis. 
 174 Harvard Collage v. Canada (Commissioner of Patents), [2002] 4 S.C.R. 45, ¶ 153-155, 
176-177. 
 175 Gervais Report, supra note 170, ¶ 17; Dimock Report, supra note 84, ¶ 12, 114. 
 176 Gold & Shortt, supra note 111, at 33-34. 
 177 Id. at 34; EI du Pont de Nemours & Co v Berkley & Co Inc., 620 F.2d 1247, 1260 n 17, 
at 128 (8th Cir 1980). 
 178 Consolboard, supra note 22; Pfizer, supra note 91; Eli Lilly 2011 FC 1288, supra note 
20; AZT, supra note 28. 
 179 35 U.S.C., supra note 104, at §112(a-b); Cre-Agri, supra note 114; Ariad Pharm., supra 
note 115. 
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synonymous with “lack [of] industrial applicability,”180 each achieving the same 
technical result of ensuring fulfillment of the promise of the patent. 
Lastly, a critical consideration in the overall analysis hinges on the 
suggestion that in upholding one norm (the promise utility doctrine), the SCC has 
invariably breached another set of international legal norms – namely, FET. 
However, such a pre-emptive conclusion assumes both that international legal 
norms are fixed with objectively identifiable components, and that any perceived 
interpretive deviation by domestic courts is a ‘violation’ rather than an 
articulation of an emerging normative standard underlying opino juris.181 For 
instance, the definition of “ship” applied domestically by the Greek judiciary 
under the global regime on civil liabilities for oil pollution damage, has 
influenced the approach adopted by Parties under the International Maritime 
Organization (“IMO”) regime.182 Similarly, UK jurisprudence has at times been 
influential in the interpretation and application of law under the European Court 
of Human Rights.183 The approach adopted in Canadian jurisprudence grows 
from a unique mix of market circumstances which nurtured the promise utility 
doctrine, namely a market saturated by highly aggressive foreign competitors 
who, through use of overly aggressive patenting practices, have allowed 
vulnerabilities which invariably are exploited by domestic competitors. 
Articulation of the promise utility doctrine is responsive to speculative patent 
practices of market actors, and upholds the theoretical underpinnings of the 
patent system. 
VI. CONCLUDING THOUGHTS 
The promise utility doctrine, as seen applied in the cases of Zyprexa and 
Strattera, illustrates application of longstanding legal principles to uphold the 
public purpose of the patent bargain, and dissuade overly broad patent practices. 
Indeed, the invalidations of the 113 and 735 patents initially seemed 
counterintuitive, but were legally sound when considered juxtaposed to a 
doctrinal evaluation of the patents’ promise and relative disclosure. Practically, 
the 113 and 735 patents failed for lack of utility, not by virtue of a lack of 
commercial application, but by virtue of the fact that the patent did not 
functionally provide for the thing that was patented. The patent is an accord with 
an inventor allowing a short term monopoly over a specific new or novel process 
or thing, in exchange for accurate disclosure – in particular, based on verifiable, 
 
 180 Industrial Property Act, supra note 120, Article 12, 16, 47. 
 181 ANTONIOS TZANAKOPOULOS, PRINCIPLES ON THE ENGAGEMENT OF DOMESTIC COURTS 
WITH INTERNATIONAL LAW, PRELIMINARY REPORT, INTERNATIONAL LAW ASSOCIATION STUDY 
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30 (2012). 
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quantifiable, and enduring findings supporting a sound prediction – allowing 
another skilled in the art to build upon that knowledge once in the public domain. 
If a patent is allowed to make multiple expansive promised applications, then 
indeed it should be measured against the actualization of those proposals or risk, 
broadly inhibiting innovation and market competition in general. This was never 
the intention of the patent and is a distortion of the system. 
While procedural divergence may be identified across NAFTA jurisdictions 
relating to a utility, theoretically and substantively, the Parties apply arguably 
equitable technical inquiries. The invalidations of the 113 and 735 patents were 
in line with IP obligations under Chapter 17 of NAFTA, and as such, are 
exempted from consideration as expropriation under Article 1110(7). 
Furthermore, the invalidations in-and-of-themselves extinguished the valid 
property interests underlying an expropriation inquiry, with the judicial 
application of the promise utility doctrine through a practice of due process, 
upheld as a valid and proportionate exercise of domestic authority, should such 
an inquiry occur. It would be a distortion and contrary to the object and purpose 
of the treaty to suggest that the standard established under Article 1709 
accommodates overly broad or unsubstantiated patent practices. 
The promise utility doctrine demonstrates a natural and logical articulation 
of patent law which is consistent with the substantive and procedural 
requirements of NAFTA. The elements which make up the promise utility 
doctrine are derived from the longstanding synergies of inventiveness and 
adequate disclosure in relation to the patent bargain, and are grounded in the 
principle of FET treatment. In essence, the promise utility doctrine enforces the 
material point of the patent system: a specific and adequately disclosed invention 
which manifestly achieves the inventive promise of the patent. Overly broad or 
speculative patent practices have chilling effect on innovation through the 
creation of bottle-necks or inadvertent research monopolies. In an age of rapid 
technological innovation, the promise utility doctrine acts to soften the 
suppressive effects of speculative patent practices on innovation and trade in a 
manner consistent with NAFTA. 
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